Larimar doses first patient in open-label extension study of nomlabofusp for Friedreich's ataxia

Larimar Therapeutics, Inc.

First patient dosed in OLE evaluating 25 mg daily subcutaneous nomlabofusp for Friedreich's ataxia.
OLE to assess long-term safety, pharmacokinetics, and tissue frataxin levels; initial data expected Q4 2024.
Frataxin data from OLE and prior studies intended to support BLA for accelerated approval targeted H2 2025.
Nomlabofusp remains under partial clinical hold; 50 mg cohort data will be submitted to FDA for dose escalation review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.